Home
News
Create
Screeners
Insights
Gujarat Kidney and Super Speciality
130.
08
+4.14
(+3.29%)
Market Cap
₹1,025.59 Cr
PE Ratio
59.15
Industry
Healthcare Services
Buy
Sell
Company Performance:
1D
+3.29%
1M
-8.55%
6M
+24.43%
1Y
+24.43%
5Y
+24.43%
View Company Insights
Latest news about Gujarat Kidney and Super Speciality
Gujarat Kidney seeks nod to vary IPO proceeds utilization
9 days ago
Gujarat Kidney And Superspeciality Limited has initiated a remote e-voting process from June 05 to July 04, 2026, to seek shareholder approval for varying the utilization of its IPO proceeds. The company proposes to reallocate Rs 37.76 crore, utilizing Rs 6.12 crore for healthcare expansion in its subsidiary and parent company, and transferring Rs 19.02 crore to fund inorganic growth and general corporate purposes. The decision follows a review of a previous proposal to incorporate a new subsidiary, aiming to avoid duplication of resources. The results of the postal ballot will be announced on or before July 07, 2026.
Gujarat Kidney FY26 profit rises, appoints auditors
May 29, 2026
Gujarat Kidney promoters declare no encumbrance in FY26
May 28, 2026
Gujarat Kidney and Super Speciality to Deploy 100 AI-Powered Haemodialysis Machines Across Gujarat Network
May 15, 2026
Gujarat Kidney and Super Speciality Limited Postal Ballot Results: All Resolutions Approved
Apr 25, 2026
More news about Gujarat Kidney and Super Speciality
22
Apr 26
Gujarat Kidney Pays Rs 20,000 Fines to BSE and NSE for Board Meeting Delay
Gujarat Kidney and Super Speciality Limited has paid Rs 20,000 in total fines to BSE and NSE for failing to provide prior intimation about board meetings under SEBI Regulation 29(2)/29(3). The penalties of Rs 10,000 each were imposed on April 15, 2026, and paid via NEFT on April 16, 2026. The company confirmed no impact on financial, operational, or other activities.
07
Apr 26
Gujarat Kidney and Super Speciality Limited Submits SEBI Compliance Certificate for Q4FY26
Gujarat Kidney and Super Speciality Limited has submitted its mandatory SEBI compliance certificate for Q4FY26, confirming all shares are in electronic form. The certificate, issued by registrar MUFG Intime India Private Limited on April 6, 2026, was submitted to BSE and NSE on April 7, 2026, fulfilling Regulation 74(5) requirements for the quarter ended March 31, 2026.
26
Mar 26
Gujarat Kidney Completes Postal Ballot Notice Dispatch for IPO Fund Reallocation
Gujarat Kidney and Super Speciality Limited has completed the dispatch of its postal ballot notice to shareholders, announcing through newspaper publications on March 26, 2026. The company seeks approval for reallocating ₹3,692.50 lakhs of unutilized IPO funds from women's hospital and robotics equipment to developing a multi-specialty hospital in Bharuch and dialysis services collaboration. The e-voting process runs from March 27 to April 25, 2026, with results expected within two working days.
23
Mar 26
Gujarat Kidney and Super Speciality Limited Acquires Parekhs Hospital for ₹77 Crore
Gujarat Kidney and Super Speciality Limited completed acquisition of Parekhs Hospital Private Limited as wholly owned subsidiary on March 22, 2026, for ₹77 crore cash consideration. The target company, incorporated in 2006, operates in medical and healthcare services with revenues of ₹25.67 crore in FY25. The strategic acquisition aims to strengthen presence in healthcare sector and diversify business portfolio.
21
Mar 26
Gujarat Kidney Pays ₹6.61 Lakh Penalty to NSE and BSE for Regulatory Non-Compliance
Gujarat Kidney and Super Speciality Limited has completed payment of regulatory penalties totaling ₹6,60,800 to NSE and BSE for failing to submit quarterly financial results within prescribed timelines. The company paid ₹3,30,400 to each exchange via RTGS on March 20, 2026, following penalty notices received on March 17, 2026, and has formally communicated the settlement to both exchanges.
19
Mar 26
Gujarat Kidney Appoints Auditors and Approves Postal Ballot with Q2 FY25 Results
Gujarat Kidney And Superspeciality Limited conducted a board meeting on March 19, 2026, appointing Mr. Dharmendra Bhaliya as Secretarial Auditor and Mr. Siddharth Atulbhai Shah as Internal Auditor for FY 2025-26. The board also approved postal ballot notice and ratified Q2 FY25 financial results, which showed consolidated revenue growth of 37.40% to ₹1,292.88 lacs despite a decline in net profit.
13
Mar 26
Gujarat Kidney And Super Speciality Limited Reports Mixed Q2FY26 Results with Revenue Decline
Gujarat Kidney And Super Speciality Limited reported Q2FY26 standalone revenue of ₹964.26 lacs, up 2.47% YoY, but net profit declined 22.17% to ₹230.12 lacs due to rising expenses. Half-year performance showed stronger growth with revenue increasing 12.97% to ₹2,109.25 lacs and net profit rising 10.12% to ₹620.10 lacs. Consolidated results demonstrated significant revenue growth of 37.40% to ₹1,292.88 lacs, reflecting successful expansion through subsidiaries, though profitability remained under pressure with EPS declining across both standalone and consolidated operations.
Gujarat Kidney and Super Speciality
130.
08
+
4.
14
(+
3.
29
%)
1 Year Returns:
+24.43%
Industry Peers
Apollo Hospitals
8,498.00
(+
0.
06
%)
Max Healthcare Institute
1,012.45
(+
0.
28
%)
Fortis Healthcare
990.35
(+
0.
14
%)
Aster DM Healthcare
814.95
(+
0.
15
%)
Narayana Hrudayalaya
1,893.90
(+
1.
90
%)
Global Health
1,235.10
(+
0.
49
%)
Krishna Institute of Medical Sciences
785.10
(+
2.
57
%)
Dr. Agarwal's Health Care
439.75
(+
0.
08
%)
Rainbow Childrens Medicare
1,365.00
(+
1.
87
%)
Park Medi World
274.60
(+
0.
49
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar